ICON PLC

Icon PLC launches senior notes offering to repay loans and strengthen credit, reinforcing its leadership in global clinical research and future growth.

ICON PLC is set to release its quarterly financial results on July 23, 2025, with analysts predicting a significant increase in earnings per share and a slight decrease in revenue.

ICON PLC is a leading contract clinical research services company with a strong track record of performance, innovation, and customer satisfaction, making it a beacon of excellence in the global pharmaceutical industry.

ICON PLC is a leading contract clinical research service provider that has established itself as a global powerhouse in the health care industry, with a strong financial performance and strategic market positioning.

ICON PLC is a leading contract clinical research service provider in the life sciences tools and services sector, known for its strategic growth, financial resilience, and commitment to delivering exceptional clinical research services.

ICON PLC has released its 2024 ICON Cares Report, highlighting the company’s achievements in sustainability and innovation, including a 72/100 EcoVadis score and recognition as one of TIME magazine’s World’s Best Companies in Sustainable Growth 2025.

ICON PLC is a leading provider of contract clinical research services, with a strong global presence and robust financial performance, supporting the development of new pharmaceuticals.

ICON PLC, a contract clinical research service provider, has emphasized enhancing obesity clinical trial designs to maximize next-generation therapies, with its stock price currently at $133.96 USD.

ICON PLC faces market challenges and legal scrutiny as it navigates the healthcare industry’s digital transformation, with a focus on improving clinical trial designs and leveraging digital advancements.

ICON PLC exceeded Q1 earnings estimates, reporting a net book to bill ratio of 1.01 and $2.022 billion in net business wins, with its stock price closing at $145.21 on April 30, 2025.